Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • nivolumab-relatlimab

    - PMLiVE

    BMS granted FDA priority review for Breyanzi in marginal zone lymphoma

    The disease accounts for approximately 7% of all non-Hodgkin lymphoma cases

    - PMLiVE

    BMS and Bain Capital launch new company to develop immunology therapies

    The newly formed company has in-licensed five investigational immunology drugs from BMS

    - PMLiVE

    BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

    BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer

    - PMLiVE

    Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

    Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

    - PMLiVE

    Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

    Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

    - PMLiVE

    Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

    The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

    - PMLiVE

    BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

    Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

    - PMLiVE

    BMS receives FDA approval for immunotherapy combination in liver cancer

    Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

    - PMLiVE

    BMS granted FDA approval for immunotherapy combination in colorectal cancer

    More than 154,000 cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

    Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

    - PMLiVE

    Bristol Myers Squibb granted EC approval for Breyanzi in follicular lymphoma

    The disease accounts for up to 30% of non-Hodgkin lymphoma cases

    - PMLiVE

    BMS granted EC approval for immunotherapy combination in liver cancer

    More than 866,100 cases of the disease were diagnosed globally in 2022

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links